Hazard Information
Description
Emibetuzumab is a bivalent antibody that blocks HGF- and MET-receptor interaction,
leading to MET internalization and degradation.
Uses
Emibetuzumab (LY2875358) is a humanized bivalent MET antibody (IgG4 type). Emibetuzumab shows high neutralization and internalization activities, resulting in inhibition of both HGF-dependent and HGF-independent MET pathway activation and tumor growth. Emibetuzumab can be used in study of cancer[1].
Clinical Use
A phase I study determined a tolerable dose for emibetuzumab to be 700–2000 mg as a monotherapy and
in combination with erlotinib in NSCLC patients. It is currently being investigated in phase II in combination with erlotinib.
in vivo
Emibetuzumab (LY2875358) (10 mg/kg; i.v.; once a week for 5 weeks) inhibits in vivo growth of glioblastoma U87MG xenograft tumors in mice[1].
Emibetuzumab (10 or 20 mg/kg; i.v.; single) downregulates levels of MET and pMET in the tumors of mice[1].
Emibetuzumab (10 mg/kg; i.v.; once a week for 3, 5 or 6 weeks) exhibits antitumor effects on MET-amplified xenograft mouse tumor models[1].
| Animal Model: | Athymic nude mice (U87MG tumor xenograft model)[1]. |
| Dosage: | 10 mg/kg |
| Administration: | Intravenous injection, once a week for 5 weeks. |
| Result: | Demonstrated a significant inhibition of tumor growth. |
| Animal Model: | Athymic nude mice (MKN45 xenograft tumor model)[1]. |
| Dosage: | 10 or 20 mg/kg |
| Administration: | Intravenous injection, single. |
| Result: | Reduced MET and pMET in the tumors by approximately 50% at both the 10 and 20 mg/kg doses by 72 hours post dose, and the reductions persisted to 14 days. |
| Animal Model: | Athymic nude mice (MET-amplified xenograft mouse tumor models)[1]. |
| Dosage: | 10 mg/kg |
| Administration: | Intravenous injection, once a week for 3, 5 or 6 weeks. |
| Result: | Resulted in a marked reduction in tumor growth in the MKN45/SNU-5/EBC-1 gastric xenograft tumors. |
References
[1] Liu L, et al. LY2875358, a neutralizing and internalizing anti-MET bivalent antibody, inhibits HGF-dependent and HGF-independent MET activation and tumor growth. Clin Cancer Res. 2014 Dec 1;20(23):6059-70. DOI:10.1158/1078-0432.CCR-14-0543
Supplier
Shanghai YuanYe Biotechnology Co., Ltd.
Telephone021-61312847; 18021002903
Websitehttp://www.shyuanye.com
ShangHai Biochempartner Co.,Ltd
Telephone17754423994 17754423994
Websitehttps://www.biochempartner.com
Guangzhou Hongyuan Chemical Co.,Ltd
Telephone 15817493340
Websitehttps://www.chemicalbook.com/ShowSupplierProductsList1222417/0.htm
Wuhan Chemstan Biotechnology Co., Ltd.
Telephone027-65317797 15926423062
Websitehttp://www.chemstan.com/
TargetMol Chemicals Inc.
Telephone 4008200310
Websitehttps://www.targetmol.cn/
Biolab Reagents
Telephone18108604356 18108604356
Websitehttps://www.biolabreagent.com/
Wuhan Jingkangen Biomedical Technology Co., Ltd
Telephone13720134139 086-15871494362 13720134139
Websitehttps://www.jknbiochem.com
Shanghai Yifei Biotechnology Co. , Ltd.
Telephone021-65675885 18964387627
Websitehttp://www.efebio.com
Shanghai Aladdin Biochemical Technology Co.,Ltd.
Telephone400-6206333 13167063860
Websitehttp://www.aladdin-e.com/
Changsha Fuzhen Biotechnology Co.，LTD
Telephone13823398779 13823398779
Websitehttps://www.chemicalbook.com/supplier/25777903/
Olix (Shanghai) Pharmaceutical Technology Co., Ltd
Telephone 17316404525
Websitehttps://www.olix.cn
Wanxin Biotechnology (Jiaxing) Co., LTD
Telephone0573-83568680 18057391398
Website
Atagenix Laboratories
Telephone027-87008169 17762441161
Websitehttps://www.abinscience.com/
Sangon Biotech (Shanghai) Co.,Ltd.
Telephone400-821-026
Websitehttp://www.sangon.com
AntibodySystem Laboratories SAS
Telephone 33175446423
Websitehttp://www.antibodysystem.com
Biosynth Biological Technology (Suzhou) Co Ltd
Telephone 51288865780
Websitehttp://www.biosynth.com
Cell Sciences
Telephone 9785721070
Websitehttp://www.cellsciences.com
1of4
PROMPT×
PROMPT
The What'sApp is temporarily not supported in mainland China
The What'sApp is temporarily not supported in mainland China
Cancel
Determine